Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

NCT07589530 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Metastatic Solid Tumors
TROP2-Expressing Solid Tumors

Interventions

BIOLOGICAL: EB-NK-301
DRUG: Fludarabine

Sponsor

Beijing Biotech